Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Anaplastic Lymphoma Kinase-positive: later-stage trial registry

1 of 1 indexed Anaplastic Lymphoma Kinase-positive trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Anaplastic Lymphoma Kinase-positive: 1 US clinical trial tracked, 1 recruiting.

Anaplastic Lymphoma Kinase-positive is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Nuvalent, running 1 of these trials.

Enrollment posture brief

Registry condition anaplastic-lymphoma-kinase-positive

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Anaplastic Lymphoma Kina (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Anaplastic Lymphoma Kinase-positive

Anaplastic Lymphoma Kinase-positive lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Anaplastic Lymphoma Kinase-positive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Anaplastic Lymphoma Kinase-positive is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Nuvalent 1 trials

Named interventions

Most-linked intervention names on Anaplastic Lymphoma Kinase-positive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Neladalkib (NVL-655) Drug
1 trials
Alectinib Drug
1 trials

US sites by state

Facility locations filed on Anaplastic Lymphoma Kinase-positive trials. A trial with sites in several states counts in each.

Virginia 1 trials
Tennessee 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials
Missouri 1 trials
Michigan 1 trials
Massachusetts 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Anaplastic Lymphoma Kinase-positive page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Anaplastic Lymphoma Kinase-positive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Nuvalent sponsors the most Anaplastic Lymphoma Kinase-positive trials on record, review their full trial history before evaluating a specific study. See Nuvalent's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anaplastic Lymphoma Kinase-positive condition card totals 1 registered trials; most-linked intervention Neladalkib (NVL-655); top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.